PMID 33237064 Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials Meta-analysis · Food Funct, 2020 Combined calcium and vitamin D raised total, lumbar, and femoral-neck BMD in postmenopausal women and modestly lowered hip fracture (RR 0.86); the BMD benefit was largest from fortified dairy.
Key summary
An RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects. meta-analysisA statistical synthesis combining results of multiple studies into one conclusion. of the skeletal effects of combined calcium plus vitamin D in postmenopausal women. Total BMD (SMD 0.54), lumbar spine (0.23), arms (0.46), and femoral neck (0.19) rose significantly and hip fracture fell (RR 0.86). The femoral-neck gain was clear only at vitamin D doses of 400 IUInternational unit - a measure of a vitamin biological activity; for vitamin E, 1 IU is roughly 0.45 to 0.67 mg depending on the form. or less, calcium alone had no effect, and the BMD benefit was largest from dairy products fortified with calcium and vitamin D.
Show original abstract
OBJECTIVE: The aim of the present study was to explore whether combined calcium and vitamin D supplementation is beneficial for osteoporosis in postmenopausal women. METHODS: We searched the PubMed, Cochrane library, Web of science and Embase databases and reference lists of eligible articles up to Feb, 2020. Randomized controlled trials (RCTs) evaluating the effect of combined calcium and vitamin D on osteoporosis in postmenopausal women were included in the present study. RESULTS: Combined calcium and vitamin D significantly increased total bone mineral density (BMD) (standard mean differences (SMD) = 0.537; 95% confidence interval (CI): 0.227 to 0.847), lumbar spine BMD (SMD = 0.233; 95% CI: 0.073 to 0.392; P < 0.001), arms BMD (SMD = 0.464; 95% CI: 0.186 to 0.741) and femoral neck BMD (SMD = 0.187; 95% CI: 0.010 to 0.364). It also significantly reduced the incidence of hip fracture (RR = 0.864; 95% CI: 0.763 to 0.979). Subgroup analysis showed that combined calcium and vitamin D significantly increased femoral neck BMD only when the dose of the vitamin D intake was no more than 400 IU d-1 (SMD = 0.335; 95% CI: 0.113 to 0.558), but not for a dose more than 400 IU d-1 (SMD = -0.098; 95% CI: -0.109 to 0.305), and calcium had no effect on the femoral neck BMD. Subgroup analysis also showed only dairy products fortified with calcium and vitamin D had a significant influence on total BMD (SMD = 0.784; 95% CI: 0.322 to 1.247) and lumbar spine BMD (SMD = 0.320; 95% CI: 0.146 to 0.494), but not for combined calcium and vitamin D supplement. CONCLUSION: Dairy products fortified with calcium and vitamin D have a favorable effect on bone mineral density. Combined calcium and vitamin D supplementation could prevent osteoporosis hip fracture in postmenopausal women. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 29279934 Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis Meta-analysis · JAMA, 2017 33 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s, 51,145 people - in community-dwelling older adults, neither calcium, vitamin D, nor the combination lowered hip, nonvertebral, vertebral, or total fracture risk; does not support routine supplementation.
Key summary
A large meta-analysisA statistical synthesis combining results of multiple studies into one conclusion. of whether calcium, vitamin D, or the combination reduces fractures in community-dwelling adults over 50 (33 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s, 51,145 people). For the primary outcome of hip fracture, calcium (RR 1.53), vitamin D (1.21), and the combination (1.09) all showed no significant reduction versus placeboAn inert dummy treatment used as the comparison baseline. or no treatment, and the same held for nonvertebral, vertebral, and total fractures. Results were consistent regardless of dose, sex, fracture history, dietary calcium, and baseline vitamin D. The authors concluded the findings do not support routine use of these supplements in community-dwelling older people.
Show original abstract
IMPORTANCE: The increased social and economic burdens for osteoporosis-related fractures worldwide make the prevention of such injuries a major public health goal. Previous studies have reached mixed conclusions regarding the association between calcium, vitamin D, or combined calcium and vitamin D supplements and fracture incidence in older adults. OBJECTIVE: To investigate whether calcium, vitamin D, or combined calcium and vitamin D supplements are associated with a lower fracture incidence in community-dwelling older adults. DATA SOURCES: The PubMed, Cochrane library, and EMBASE databases were systematically searched from the inception dates to December 24, 2016, using the keywords calcium, vitamin D, and fracture to identify systematic reviews or meta-analyses. The primary randomized clinical trials included in systematic reviews or meta-analyses were identified, and an additional search for recently published randomized trials was performed from July 16, 2012, to July 16, 2017. STUDY SELECTION: Randomized clinical trials comparing calcium, vitamin D, or combined calcium and vitamin D supplements with a placebo or no treatment for fracture incidence in community-dwelling adults older than 50 years. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers performed the data extraction and assessed study quality. A meta-analysis was performed to calculate risk ratios (RRs), absolute risk differences (ARDs), and 95% CIs using random-effects models. MAIN OUTCOMES AND MEASURES: Hip fracture was defined as the primary outcome. Secondary outcomes were nonvertebral fracture, vertebral fracture, and total fracture. RESULTS: A total of 33 randomized trials involving 51 145 participants fulfilled the inclusion criteria. There was no significant association of calcium or vitamin D with risk of hip fracture compared with placebo or no treatment (calcium: RR, 1.53 [95% CI, 0.97 to 2.42]; ARD, 0.01 [95% CI, 0.00 to 0.01]; vitamin D: RR, 1.21 [95% CI, 0.99 to 1.47]; ARD, 0.00 [95% CI, -0.00 to 0.01]. There was no significant association of combined calcium and vitamin D with hip fracture compared with placebo or no treatment (RR, 1.09 [95% CI, 0.85 to 1.39]; ARD, 0.00 [95% CI, -0.00 to 0.00]). No significant associations were found between calcium, vitamin D, or combined calcium and vitamin D supplements and the incidence of nonvertebral, vertebral, or total fractures. Subgroup analyses showed that these results were generally consistent regardless of the calcium or vitamin D dose, sex, fracture history, dietary calcium intake, and baseline serum 25-hydroxyvitamin D concentration. CONCLUSIONS AND RELEVANCE: In this meta-analysis of randomized clinical trials, the use of supplements that included calcium, vitamin D, or both compared with placebo or no treatment was not associated with a lower risk of fractures among community-dwelling older adults. These findings do not support the routine use of these supplements in community-dwelling older people. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 35842938 What is the impact of daily oral supplementation of vitamin D3 (cholecalciferol) plus calcium on the incidence of hip fracture in older people? A systematic review and meta-analysis Meta-analysis · Int J Older People Nurs, 2023 7 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s, 12,620 people - vitamin D3 800 IUInternational unit - a measure of a vitamin biological activity; for vitamin E, 1 IU is roughly 0.45 to 0.67 mg depending on the form. plus calcium 1,200 mg significantly reduced hip fracture (OR 0.75) and nonvertebral fracture (OR 0.80); the 1,000 mg calcium combination showed no effect, and femoral-neck BMD did not increase.
Key summary
A meta-analysisA statistical synthesis combining results of multiple studies into one conclusion. of whether vitamin D3 plus calcium reduces hip fracture in people over 65 (7 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s, 12,620 people). The combination significantly lowered hip fracture (OR 0.75) and nonvertebral fracture (OR 0.80). Vitamin D3 800 IUInternational unit - a measure of a vitamin biological activity; for vitamin E, 1 IU is roughly 0.45 to 0.67 mg depending on the form. plus calcium 1,200 mg (OR 0.69) was effective, whereas 800 IU plus calcium 1,000 mg was not (OR 1.08). Femoral-neck BMD, however, did not increase significantly. The authors add that supplementation is only one element of fracture prevention alongside exercise and nutrition.
Show original abstract
INTRODUCTION: Hip fractures have a huge impact in reducing the quality of life and increasing mortality. This review aims to assess the impact of daily oral supplementation of vitamin D3 plus calcium on the incidence of hip fracture in people over 65 years. METHODS: PRISMA guidelines were followed and RCTs that evaluated the effectiveness of daily oral supplementation of vitamin D3 plus calcium in preventing hip fracture in adults over 65 years were included in the study. The databases such as Cochrane Library, Embase, Medline, PubMed, CINAHL, Web of Science and Scopus were searched from October 2019- January 2020.The Cochrane risk of bias tool was used to check the quality of the included studies. A meta-analysis with fixed effect model using Review Manager (Revman 5.3) was used to analyse the data. RESULTS: The meta-analysis of seven RCTs on vitamin D3 plus calcium supplementation and hip fracture (n = 12,620) identified odds ratio (OR) of 0.75; 95% Confidence interval (CI): 0.64, 0.87; p = .0003. Daily oral supplementation of 800 IU of Vitamin D3 plus 1200 mg of calcium was found more effective (n = 5676 participants; OR = 0.69; 95% CI: 0.58, 0.82; p < .0001) than daily oral supplementation of 800 IU of Vitamin D3 plus 1000 mg of calcium (n = 6555,OR = 1.08; 95% CI: 0.74, 1.56; p = .70) in reducing hip fracture. A meta-analysis of the seven RCTs to identify the incidence of non-vertebral fracture gave the OR of 0.80; 95% CI: 0.72, 0.89; p < .0001. A meta-analysis of three RCTs on femoral neck bone mineral density (BMD) (n = 483) gave a mean difference of 1.21; 95% CI: -0.79, 3.20; p = .24. CONCLUSION: Daily oral supplementation 800 IU of vitamin D3 plus 1200 mg of calcium reduces hip fracture and non-vertebral fracture in older people. Administering vitamin D3 and calcium supplements had no effect in increasing the femoral neck BMD. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 18254022 Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps Cochrane review · Cochrane Database Syst Rev, 2008 2 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s in people with prior adenomas, 1,346 people - calcium reduced recurrent colorectal adenoma (OR 0.74), but this is not enough to recommend general use to prevent colorectal cancer.
Key summary
A CochraneAn international network that rigorously reviews and synthesizes evidence. systematic review of whether dietary calcium supplementation reduces colorectal cancer and adenomatous polyps. Pooling two well-designed, double-blind, placeboAn inert dummy treatment used as the comparison baseline.-controlled RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s in people with prior adenomas (1,346 people, calcium 1,200-2,000 mg/day, 3-4 years) showed reduced recurrent colorectal adenoma (OR 0.74). The authors concluded that while calcium may reduce adenomas to a moderate degree, the evidence is not sufficient to recommend general use of calcium supplements to prevent colorectal cancer.
Show original abstract
BACKGROUND: Several dietary factors have been considered to be involved in the increasing incidence of colorectal cancer in industrialised countries. Experimental and epidemiological evidence has been suggestive but not conclusive for a protective role for high dietary calcium intake. Intervention studies with colorectal cancer as an endpoint are difficult to perform owing to the large number of patients and the long follow-up required; studies using the appearance of colorectal adenomatous polyps as a surrogate endpoint are therefore considered in reviewing the existing evidence. OBJECTIVES: This systematic review aims to assess the effect of supplementary dietary calcium on the incidence of colorectal cancer and the incidence or recurrence of adenomatous polyps. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register, the Cochrane Colorectal Cancer Group specialised register, MEDLINE, Cancerlit , and Embase, to July 2007. The reference lists of identified studies were inspected for further studies, and the review literature was scrutinized. SELECTION CRITERIA: Randomised controlled trials of the effects of dietary calcium on the development of colonic cancer and adenomatous polyps in humans are reviewed. Studies of healthy adults and studies of adults at higher risk of colon cancer due to family history, previous adenomatous polyps, or inflammatory bowel disease were considered; data from subjects with familial polyposis coli are excluded. The primary outcomes were the occurrence of colon cancer, and occurrence or recurrence of any new adenomas of the colon. Secondary outcomes were any adverse event that required discontinuation of calcium supplementation, and drop-outs before the end of the study. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data, assessed trial quality and resolved discrepancies by consensus. The outcomes were reported as odds ratios (OR) with 95% confidence intervals (CI). The data were combined with the fixed effects model. MAIN RESULTS: Two studies with 1346 subjects met the inclusion criteria. Both trials were well designed, double - blind, placebo controlled trials, included participants with previous adenomas. The doses of supplementary elemental calcium used were 1200 mg daily for a mean duration of 4 years, and 2000 mg/day for three years. The rates of loss to follow -up were 14 % and 11%. For the development of recurrent colorectal adenoma, a reduction was found (OR 0.74, CI 0.58,0.95) when the results from both trials were combined. AUTHORS' CONCLUSIONS: Although the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 30117164 Body mass index, calcium supplementation and risk of colorectal adenomas RCT reanalysis · Int J Cancer, 2019 In the recent VCPPS trial, calcium 1,200 mg/day did not significantly reduce adenomas; the drop in high-risk findings appeared only in normal-weight people (BMI modified the effect).
Key summary
A reanalysis of two RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s (CPPS and VCPPS) explaining why calcium's adenoma effect differed between trials, using body mass index (BMI). In the recent VCPPS, calcium 1,200 mg/day did not significantly reduce adenomas, and one reason was that it had more obese participants than the earlier CPPS. In both trials, high-risk findings (advanced or multiple adenomas) fell 44-56% in normal-weight participants but showed no benefit in overweight or obese people. The authors concluded that 1,200 mg/day calcium may reduce colorectal adenoma risk only in normal-weight individuals.
Show original abstract
Calcium supplementation (1,200 mg/day) did not significantly reduce colorectal adenomas in our recent randomized, controlled trial (Vitamin D/Calcium Polyp Prevention Study, VCPPS, 2004-2013) in contrast to our previous trial (Calcium Polyp Prevention Study, CPPS, 1988-1996). To reconcile these findings, we identified participant characteristics that differed between the study populations and modified the effect of calcium supplementation on adenomas or high-risk findings (advanced or multiple adenomas). Compared to the CPPS, more participants in the VCPPS were obese (body mass index (BMI) ≥30 kg/m2 ; 37.5% vs. 24.4%) and fewer had normal BMI (BMI <25 kg/m2 ; 18.5% vs. 31%). BMI appeared to modify the effect of calcium supplementation on adenomas and especially on high risk-findings: in the VCPPS, there was a 44% reduction in high-risk findings among individuals whose BMI was normal (RR = 0.56, 95% CI = 0.26-1.23), but not among overweight (RR = 1.09, 95% CI = 0.62-1.91) or obese (RR = 1.54, 95% CI = 0.92-2.57) individuals (pinteraction = 0.03). Similarly, in the CPPS, there was a 56% reduction in high-risk findings among individuals whose BMI was normal (RR = 0.44, 95% CI = 0.26-0.74), but not among overweight (RR = 0.87, 95% CI = 0.55-1.39) or obese (RR = 1.02, 95% CI = 0.57-1.82) individuals (pinteraction = 0.02). Standardization of each trial's findings to the BMI distribution in the other attenuated calcium's protective effect on adenomas in the CPPS but enhanced it in the VCPPS. In conclusion, 1,200 mg/day calcium supplementation may reduce risk of colorectal adenomas among those with normal BMI but not in overweight or obese individuals; and differences in BMI distribution partially account for the apparent difference in calcium efficacy between the two trials. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 20671013 Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis Meta-analysis · BMJ, 2010 15 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s - calcium supplements alone (>=500 mg/day) without vitamin D were associated with more myocardial infarctionA heart attack - death of heart muscle from blocked blood flow. (patient-level hazard ratio 1.31); the paper that sparked the cardiovascular safety debate.
Key summary
A patient- and trial-level meta-analysisA statistical synthesis combining results of multiple studies into one conclusion. of whether calcium supplements increase cardiovascular events (15 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s). In patient-level data (5 trials, 8,151 people), the calcium group had more myocardial infarctionA heart attack - death of heart muscle from blocked blood flow. than placeboAn inert dummy treatment used as the comparison baseline. (hazard ratio 1.31), while stroke, the composite endpoint, and death showed only non-significant increases. Trial-level data likewise showed an increase in myocardial infarction (relative risk 1.27). The trials used calcium supplements of >=500 mg/day given without vitamin D. The authors stated that calcium supplements (without coadministered vitamin D) are associated with increased myocardial-infarction risk and that their role in osteoporosis management warrants reassessment.
Show original abstract
OBJECTIVE: To investigate whether calcium supplements increase the risk of cardiovascular events. DESIGN: Patient level and trial level meta-analyses. DATA SOURCES: Medline, Embase, and Cochrane Central Register of Controlled Trials (1966-March 2010), reference lists of meta-analyses of calcium supplements, and two clinical trial registries. Initial searches were carried out in November 2007, with electronic database searches repeated in March 2010. STUDY SELECTION: Eligible studies were randomised, placebo controlled trials of calcium supplements (>or=500 mg/day), with 100 or more participants of mean age more than 40 years and study duration more than one year. The lead authors of eligible trials supplied data. Cardiovascular outcomes were obtained from self reports, hospital admissions, and death certificates. RESULTS: 15 trials were eligible for inclusion, five with patient level data (8151 participants, median follow-up 3.6 years, interquartile range 2.7-4.3 years) and 11 with trial level data (11 921 participants, mean duration 4.0 years). In the five studies contributing patient level data, 143 people allocated to calcium had a myocardial infarction compared with 111 allocated to placebo (hazard ratio 1.31, 95% confidence interval 1.02 to 1.67, P=0.035). Non-significant increases occurred in the incidence of stroke (1.20, 0.96 to 1.50, P=0.11), the composite end point of myocardial infarction, stroke, or sudden death (1.18, 1.00 to 1.39, P=0.057), and death (1.09, 0.96 to 1.23, P=0.18). The meta-analysis of trial level data showed similar results: 296 people had a myocardial infarction (166 allocated to calcium, 130 to placebo), with an increased incidence of myocardial infarction in those allocated to calcium (pooled relative risk 1.27, 95% confidence interval 1.01 to 1.59, P=0.038). CONCLUSIONS: Calcium supplements (without coadministered vitamin D) are associated with an increased risk of myocardial infarction. As calcium supplements are widely used these modest increases in risk of cardiovascular disease might translate into a large burden of disease in the population. A reassessment of the role of calcium supplements in the management of osteoporosis is warranted. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 37743221 Association Between Calcium Supplementation and the Risk of Cardiovascular Disease and Stroke: A Systematic Review and Meta-Analysis Meta-analysis · Heart Lung Circ, 2023 12 RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s - no association between calcium supplementation and myocardial infarctionA heart attack - death of heart muscle from blocked blood flow., stroke, heart failureA condition in which the heart cannot pump enough blood to meet the body's needs., or death; contradicts the 2010 cardiovascular concern.
Key summary
A meta-analysisA statistical synthesis combining results of multiple studies into one conclusion. re-synthesizing the relationship between calcium supplementation and cardiovascular disease and stroke using RCTRandomized controlled trial - a high-reliability trial that randomly assigns participants to compare effects.s only (12 RCTs). Calcium supplementation was not associated with myocardial infarctionA heart attack - death of heart muscle from blocked blood flow., total stroke, heart-failure admission, or all-cause/cardiovascular death. Subgroup analyses by calcium monotherapy versus co-therapy with vitamin D, sex, follow-up duration, and region did not change the findings. The authors concluded that calcium supplementation was not associated with cardiovascular events and that further study is needed to reconcile the contradictory results since 2010.
Show original abstract
BACKGROUND: Some observational studies and randomised controlled trials (RCTs) have reported an association between calcium supplementation and increased risk of cardiovascular disease. Previous meta-analyses on the topic, based on data from RCTs and observational studies, have contradictory findings. This meta-analysis was conducted to determine the difference in associated risks of calcium supplementation with cardiovascular disease and stroke in RCTs. METHODS: Relevant studies published from database inception to 6 August 2021 were sourced from PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials. Any RCTs focusing on the relationship between calcium supplementation and incidence of cardiovascular disease or stroke were included. Articles were screened independently by two authors, according to the PICO criteria, with disagreements resolved by a third author. RESULTS: Twelve RCTs were included in the meta-analysis. Calcium supplementation was not associated with myocardial infarction, total stroke, heart failure admission, and all-cause/cardiovascular mortality. Subgroup analysis focusing on calcium monotherapy/calcium co-therapy with vitamin D, female sex, follow-up duration, and geographical region did not affect the findings. CONCLUSION: Calcium supplementation was not associated with myocardial infarction, total stroke, heart failure admission, and cardiovascular/all-cause mortality. Further studies are required to examine and understand these associations. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 34959915 Calcium and Vitamin D Supplementation and Their Association with Kidney Stone Disease: A Narrative Review Narrative review · Nutrients, 2021 Calcium taken with meals binds oxalate in the gut and lowers stone risk, but supplements taken between meals may raise urinary calcium and risk; vitamin D supplements can worsen risk in those prone to hypercalciuria.
Key summary
A narrative review of how calcium and vitamin D supplementation relate to kidney stone disease. A low-calcium diet is not advised even for stone formers, and balanced calcium intake binds oxalate in the gut, reducing its absorption and urinary excretion and lowering stone risk. However, calcium supplements taken separately between meals may raise urinary calcium without the oxalate-binding benefit. The review notes that vitamin D supplements may increase stone risk in people prone to hypercalciuria.
Show original abstract
Kidney stone disease is a multifactorial condition influenced by both genetic predisposition and environmental factors such as lifestyle and dietary habits. Although different monogenic polymorphisms have been proposed as playing a causal role for calcium nephrolithiasis, the prevalence of these mutations in the general population and their complete pathogenetic pathway is yet to be determined. General dietary advice for kidney stone formers includes elevated fluid intake, dietary restriction of sodium and animal proteins, avoidance of a low calcium diet, maintenance of a normal body mass index, and elevated intake of vegetables and fibers. Thus, balanced calcium consumption protects against the risk for kidney stones by reducing intestinal oxalate availability and its urinary excretion. However, calcium supplementation given between meals might increase urinary calcium excretion without the beneficial effect on oxalate. In kidney stone formers, circulating active vitamin D has been found to be increased, whereas higher plasma 25-hydroxycholecalciferol seems to be present only in hypercalciuric patients. The association between nutritional vitamin D supplements and the risk for stone formation is currently not completely understood. However, taken together, available evidence might suggest that vitamin D administration worsens the risk for stone formation in patients predisposed to hypercalciuria. In this review, we analyzed and discussed available literature on the effect of calcium and vitamin D supplementation on the risk for kidney stone formation. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ PMID 36906146 Kidney Stone Prevention Review · Adv Nutr, 2023 A comprehensive stone-prevention review - recommends sufficient dietary calcium at 1,000-1,200 mg/d plus fluid, sodium, and oxalate management, and advises avoiding vitamin C and D supplements.
Key summary
A review synthesizing kidney-stone prevention strategies. The common risk across all stones is low urine output and dehydration, while the major risks for calcium stones are hypercalciuria, hyperoxaluria, and hypocitraturia. For prevention it recommends adequate fluid (2.5-3.0 L/day), 1,000-1,200 mg of dietary calcium a day, limiting sodium, animal protein, and oxalate-rich foods, and increasing citrus fruit, and specifically advises avoiding vitamin C and D supplements. It shows that meeting calcium needs 'in adequate amounts from food' is the basis of stone prevention.
Show original abstract
Kidney stone disease (KSD) (alternatively nephrolithiasis or urolithiasis) is a global health care problem that affects people in almost all of developed and developing countries. Its prevalence has been continuously increasing with a high recurrence rate after stone removal. Although effective therapeutic modalities are available, preventive strategies for both new and recurrent stones are required to reduce physical and financial burdens of KSD. To prevent kidney stone formation, its etiology and risk factors should be first considered. Low urine output and dehydration are the common risks of all stone types, whereas hypercalciuria, hyperoxaluria, and hypocitraturia are the major risks of calcium stones. In this article, up-to-date knowledge on strategies (nutrition-based mainly) to prevent KSD is provided. Important roles of fluid intake (2.5-3.0 L/d), diuresis (>2.0-2.5 L/d), lifestyle and habit modifications (for example, maintain normal body mass index, fluid compensation for working in high-temperature environment, and avoid cigarette smoking), and dietary management [for example, sufficient calcium at 1000-1200 mg/d, limit sodium at 2 or 3-5 g/d of sodium chloride (NaCl), limit oxalate-rich foods, avoid vitamin C and vitamin D supplements, limit animal proteins to 0.8-1.0 g/kg body weight/d but increase plant proteins in patients with calcium and uric acid stone and those with hyperuricosuria, increase proportion of citrus fruits, and consider lime powder supplementation] are summarized. Moreover, uses of natural bioactive products (for example, caffeine, epigallocatechin gallate, and diosmin), medications (for example, thiazides, alkaline citrate, other alkalinizing agents, and allopurinol), bacterial eradication, and probiotics are also discussed. ※ The abstract text as collected and stored via the API by the pipeline. The key summary is written based solely on this text.
View original ↗ USDA FoodData Central Tofu, raw, regular, prepared with calcium sulfate (FDC 172476)
This is a nutrient-data source (USDA FoodData Central). Verify directly in the original below.
View original ↗ USDA FoodData Central Fish, sardine, Atlantic, canned in oil, drained solids with bone (FDC 175139)
This is a nutrient-data source (USDA FoodData Central). Verify directly in the original below.
View original ↗ USDA FoodData Central Yogurt, plain, whole milk (FDC 171284)
This is a nutrient-data source (USDA FoodData Central). Verify directly in the original below.
View original ↗ USDA FoodData Central Milk, whole, 3.25% milkfat (FDC 172217)
This is a nutrient-data source (USDA FoodData Central). Verify directly in the original below.
View original ↗ USDA FoodData Central Cheese, cheddar, sharp, sliced (FDC 170899)
This is a nutrient-data source (USDA FoodData Central). Verify directly in the original below.
View original ↗ USDA FoodData Central Kale, cooked, boiled, drained, without salt (FDC 169238)
This is a nutrient-data source (USDA FoodData Central). Verify directly in the original below.
View original ↗ 